M6A demethylase fat mass and obesity-associated protein regulates cisplatin resistance of gastric cancer by modulating autophagy activation through ULK1

Yan Zhang1,2 | Ling-xi Gao2 | Wen Wang2 | Teng Zhang2 | Fang-yi Dong3 | Wen-ping Ding1,4

Abstract
Drug resistance is an important factor for treatment failure of gastric cancer. N6-methyladenosine (m6A) is the predominant mRNA internal modification in eukaryotes. The roles of m6A modification in drug resistance of gastric cancer remains unclear. In the present study, the m6A methylated RNA level was significantly decreased while the expression of m6A demethylase fat mass and obesity-associated protein (FTO) was obviously elevated in cisplatin-resistant (SGC-7901/DDP) gastric cancer cells. Knockdown of FTO reversed cisplatin resistance of SGC-7901/DDP cells both in vitro and in vivo, which was attributed to the inhibition of Unc-51-like kinase 1 (ULK1)-mediated autophagy. Mechanistically, ULK1 expression was regulated in an FTO-m6A-dependent and YTHDF2-mediated manner. Collectively, our findings indicate that the FTO/ULK1 axis exerts crucial roles in cisplatin resistance of gastric cancer.

KEYWORDS
autophagy, cisplatin resistance, FTO, gastric cancer, ULK1

Correspondence
Fang-yi Dong, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Email: dfy01c15@rjh.com.cn

Wen-ping Ding, Department of Radiotherapy, The First Affiliated Hospital of Wannan Medical College, Yijishan Hospital, Wuhu, China. Email: dingwenping99@163.com

Funding information
Key Project Research Fund of Wannan Medical College, Grant/Award Number: WK2020ZF19; Key University Science Research Project of Anhui Province, Grant/Award Number: KJ2020A0594 and KJ2021A0827
1 | INTRODUCTION

Gastric cancer is one of the most common tumors that poses a potential threat to human health and quality of life.\(^1\,^2\) At present, platinum-based chemotherapy is commonly used for patients with gastric cancer, which can improve prognosis and prolong the survival of patients. Unfortunately, poor response to platinum-based chemotherapy is often observed in gastric cancer patients due to the primary or obtained resistance, which becomes the major cause of treatment failure.\(^3\,^4\) Over the past few decades, scientists have studied the mechanisms of cisplatin resistance. It is a complex cellular process that involves multiple pathways, including DNA repair, autophagy, and glutamine metabolism.\(^5\,^7\) Consequently, the understanding of molecular mechanisms for platinum resistance and investigating potential therapeutic targets are urgent.

Autophagy is a system of cellular degradation, which is a prevalent element of drug resistance to chemotherapy in tumor cells.\(^8\,^9\) Chemotherapeutic drugs could induce autophagy, which avoids cancer cell apoptosis, thereby producing drug resistance.\(^10\) Previous studies have shown that 5-fluorouracil induced autophagic death of gastric cancer cells and inhibited cell proliferation by upregulating Beclin1 expression by inhibiting microRNA-30.\(^11\) It was found that autophagy, which was involved in the formation and maintenance of chemotherapeutic resistance, inhibited the killing effect of imatinib on tumor cells in BCR-ABL positive chronic myelogenous leukemia.\(^12\,^13\)

Some studies have found that paclitaxel increased the expression of BECN1 and decreased P62, inducing autophagy, in both cases.\(^15\,^16\) Unc-51-like kinase 1 (ULK1) is a cytoplasmic kinase, which recruits the autophagy proteins to mediate the initiation of autophagy.\(^17\) A selective inhibitor of ULK1 (SBI0206965) significantly inhibits the progress of autophagy in cisplatin-resistant non-small-cell lung cancer (NSCLC) cells.\(^18\) In addition, knockdown of ULK1 in NSCLC cells makes cells more sensitive to cisplatin.\(^19\)

N\(^6\)-methyladenosine (m\(^6\)A), in which the sixth nitrogen (N) atom of adenine is methylated, is the most frequent modification on mRNAs in eukaryotes. Modification of m\(^6\)A is regulated by methyltransferase complex ("writers"), demethylases ("erasers"), and RNA-binding proteins ("readers").\(^20\) The main discovered components of the methyltransferases include methyltransferase-like 3 (METTL3) and METTL14, while fat mass and obesity-associated protein (FTO) and α-ketoglutarate-dependent dioxygenase homolog 5 (ALKBH5) have been identified as demethylated enzymes. The main known "reader" proteins include YTH domain families (YTHDF1, YTHDF2, and YTHDC1), which mediate mRNA stabilization.\(^21\,^22\) In the current study, we aimed to clarify the effects and mechanisms of m\(^6\)A RNA modification on autophagy-related cisplatin resistance in gastric cancer cells.

Fat mass and obesity-associated protein, the first identified m\(^6\)A demethylase, has important roles in various types of disease.\(^23\,^24\) The present study found that FTO was obviously elevated in the cisplatin-resistant (SGC-7901/DDP) gastric cancer cells. Knockdown of FTO reversed cisplatin resistance both in vitro and in vivo, which was attributed to the inhibition of ULK1-mediated autophagy. Furthermore, ULK1 expression was regulated in the FTO-m\(^6\)A-dependent and YTHDF2-mediated manner.

2 | MATERIALS AND METHODS

2.1 | Cell culture

The human gastric epithelial cell lineGES-1 and the human gastric cancer cell line SGC-7901 were obtained from the Health Science Research Resources Bank and used in our previous study.\(^26\) Cells were cultured in RPMI-1640 medium (Gibco) supplemented with 10% FBS (Lonsera). The cisplatin-resistant cell line (SGC-7901/DDP) was produced from parental SGC-7901 cells. In brief, SGC-7901 cells were subjected to increasing concentrations of cisplatin from 0.1 μM (Sigma-Aldrich) until the cells acquired resistance to 1 μM cisplatin. The cells were additionally treated with 0.5 μM cisplatin to maintain the cisplatin-resistant phenotype. The cisplatin in the medium was removed 2 weeks before other experiments.

2.2 | Cell transfection

Lentivirus (LV) carrying FTO shRNA (shFTO) or negative control shRNA (shNC) and plasmid (pCDNA3.1) carrying FTO or YTHDF2 were purchased from HanBio. The ULK1 siRNA (siULK1), YTHDF2 siRNA (siYTHDF2), and negative control siRNA (siNC) were purchased from Ribobio. Cells in 6-well culture plates were infected with lentivirus carrying shRNA for 72h. Cell transfection with plasmid and siRNA was undertaken with Lipofectamine 3000 (Invitrogen) for 48h. The procedures were carried out strictly in accordance with the manufacturer’s instructions. The FTO shRNA sequences were: #1, 5′-GGATGACTCTCATCTGAGAAGA-3′ and #2, 5′-AAGAGCAGAGCAGCATAACGTA-3′. The ULK1 siRNA sequences were: #1, 5′-CGCCTGTTCTACGAGAAGG-3′ and #2, 5′-ACCAGCGCTTGCAGAAG-3′. The YTHDF2 siRNA sequence was 5′-GACCAAGATGGCGATTGA-3′ and NC sequence was 5′-UUCUCCGAAACGUGUCAGTT-3′.

2.3 | Cell viability assay

Cell viability assays were performed using the CCK-8 method. Cells at log-phase growth were seeded into 96-well plates at 5000 cells/well. After treatment, 10 μl CCK-8 solution (Beyotime) was added into each well, followed by an additional incubation for 2h at 37°C. Finally, the 450 nm absorbance (OD) was determined using a microplate reader (Bio-Tek). The percentage cell viability was calculated. Cells were treated with different concentrations of cisplatin (0, 1, 2, 4, 8, 16, and 32 μM) for 24h. The cell viability was measured by CCK-8 after cisplatin treatment. The IC\(_{50}\) values of cisplatin were calculated.
2.4 | m^6A RNA methylation quantification

Total RNA was extracted from GES-1, SGC-7901, and SGC-7901/DDP cells using TRIzol reagent. The m^6A content in the total RNA was detected using the m^6A RNA Methylation Assay Kit (Abcam). The percentage of m^6A in total RNA was carried out using the following formula:

\[
\text{m}^6\text{A}\% = \left( \frac{\text{positive control OD} - \text{negative control OD}}{\text{positive control OD} - \text{NC OD}} \right) \times 100\%.
\]

2.5 | Western blot analysis

Cells or tumor tissues were lysed in RIPA lysis buffer with protease and phosphatase inhibitors (Beyotime). Thirty micrograms of total protein was subjected to SDS-PAGE gels and subsequently transferred to PVDF membranes. The membranes were blocked and then incubated with primary Abs overnight at 4°C. After washing three times, the membranes were incubated with the secondary Abs for 2 h at room temperature. Finally, protein bands were visualized by a chemiluminescence imaging system (Tanon) using western chemiluminescent HRP substrate (ECL, Millipore). The following Abs were purchased: METTL3, METTL14, FTO, ALKBH5, and YTHDF2 (Cat. No. ab195352, ab220030, ab126605, ab195377, and ab220163, respectively; Abcam); ULK1, LC3B, and P62/SQSTM1 (Cat. No. 8054, 3868, and 88588, respectively; Cell Signaling Technology); ATG13 pS318 (Cat. No. ab220030, ab126605, ab195377, and ab220163, respectively; Abcam); ULK1, LC3B, and P62/SQSTM1 (Cat. No. 8054, 3868, and 88588, respectively; Cell Signaling Technology).

2.6 | Transmission electron microscopy

Autophagosomes refer to endogenous substances, including damaged organelles or excess glycogen stored in cells due to physiological or pathological reasons, which can be formed by wrapping membranes of the cells themselves (such as endoplasmic reticulum or Golgi complex membranes). Under transmission electron microscopy (TEM), autophagosomes were characterized as crescent-shaped or cup-shaped double- or multilayered autophagosomes with a tendency to enclose cytoplasmic components. Cells were centrifuged and the supernatant discarded. After centrifugation, the cell clumps were fixed in 2% glutaraldehyde overnight at 4°C, then incubated in 1% osmium tetroxide for 1 h at 4°C, dehydrated in graded ethanol, saturated in graded acetone, and cut into 50-nm ultrathin sections. The autophagosomes in cells were viewed under a JEM-1010 TEM (JEOL).

2.7 | Immunofluorescence analysis

Cells were fixed with 4% paraformaldehyde and then permeabilized with Triton X-100 (Beyotime) at room temperature. Cells were incubated with anti-LC3B Abs (Abcam) at 4°C overnight after blocking with the Immunol staining blocking buffer (Beyotime) for 60 min. After washing three times with TBST solution, cells were incubated with Cy3 goat anti-rabbit IgG (Abclonal) at room temperature for 1 h. Cell nuclei were stained with DAPI (Beyotime) for 10 min at room temperature. Cells were observed under fluorescence microscope and images were collected after adding antifluorescence attenuation sealers.

2.8 | Quantitative real-time PCR

TRIzol reagent (Invitrogen) was used to extract total RNA from cells, and a reverse transcription kit (Tiangen) was used for reverse transcription. cDNA was generated according to the manufacturer’s instructions. In addition, quantitative real-time PCR (qPCR) was carried out to analyze gene expression using the SYBR Green PCR Kit (Tiangen). The PCR data were normalized to human GAPDH expression. The relative gene expression was calculated using the comparative cycle threshold (2^{-\Delta\Delta Ct}) method. The primer sequences for genes are shown as follows:

- GAPDH forward, 5′- CAGGAGGGATTGCTGATGAT-3′ and reverse, 5′- GAGGGCTGTTCACACACAC-3′; ATG5 forward, 5′- GCAGTGACAGTGCCACACAC-3′ and reverse, 5′- GAGGTGTCTTCCACATTGGCTCTA-3′; ATG7 forward, 5′- CGTTCGCCCAACAGCATCCTTC-3′ and reverse, 5′- CCTGAGGTGGTACCCATCCTTG-3′; ULK1 forward, 5′- GCTGGACCTGCTGCACTGCTC-3′ and reverse, 5′- CACCGACACACACACACAC-3′; and Beclin1 forward, 5′- CTGAGACACACTCAGGTACGTA-3′ and reverse, 5′- CTCTAGTGCCAGCTCCTTTGAC-3′.

2.9 | N^6-methyladenosine RIP qPCR assay

This procedure was undertaken with the m^6A RIP (MeRIP) kit (Bersinbio) according to the manufacturer’s instructions. Briefly, total RNA was extracted from 2 × 10^7 SGC-7901/DDP cells using TRIzol reagent, and RNA was further fragmented using ultrasound. The processed fragment size was approximately 300bp. After fragmentation, 50μl RNA samples were stored as Input samples at −80°C; the remaining RNA samples were immunoprecipitated with anti-m^6A Ab (Abcam) or anti-IgG Ab and washed with immunoprecipitation (IP) buffer. Protein A/G magnetic beads were incubated with RNA-Ab hybridization solution for 1 h at 4°C in a vertical mixer. The beads were washed three times with IP buffer and then digested with protease K at 55°C for 45 min. Supernatant was transferred to new RNase-free tubes, and RNA was purified, followed by qRT-PCR. Primer sequences were:

- ULK1 (site 1) forward, 5′- TCTGTGCTGACCTTTCTGG-3′ and reverse, 5′- GCTCAGACACACACACACACACAC-3′; ULK1 (site 2) forward, 5′- ATGGGCGGTCATCCTGG-3′ and reverse, 5′- AATTCTGTGATCCACCCAC-3′; and ULK1 (site 3)
forward, 5'-AGCCTCTCCCTCGAGATAC-3' and reverse, 5'-TG TACAAACACCCAGGCCACT-3'.

2.10 | RNA immunoprecipitation PCR

RNA immunoprecipitation was undertaken with the RIP kit (Bersinbio) according to the manufacturer's instructions. Briefly, total RNA was extracted from 2×10^7 cells using TRIzol reagent. RNA samples were divided into three: the IP group, IgG group and Input group. The Input samples were stored at -80°C. Anti-FTO, -YTHDF2, or -IgG Abs were conjugated to protein A/G magnetic beads in IP buffer for 16 h at 4°C in a vertical mixer. The RNA was eluted from the beads with protease K at 55°C for 45 min. Finally, the precipitated RNA and input RNA were detected by qRT-PCR.

2.11 | mRNA stability analysis

Cells were transfected with either the NC siRNA or YTHDF2 siRNA for 24 h and then treated with 5 μg/ml actinomycin D (MCE) to inhibit mRNA transcription. The cells were collected and total RNA was extracted by TRIzol reagent after treatment for the indicated times. The levels of mRNA were detected by qRT-PCR.

2.12 | Animals and treatments

Five-week-old male BALB/c nude mice were purchased from Hangzhou Medical College Laboratory Animal Co., Ltd. The mice were raised in pathogen-free conditions, and all the experiments were implemented according to the Guide for the Care and Use of Laboratory Animals published by the US NIH. SGC-7901/DDP cells expressing LV-shFTO or LV-shNC were re-suspended in PBS solution. A total of 5×10^7 cells in 200 μl PBS were injected subcutaneously into the flanks of nude mice. After injection, cisplatin treatment was initiated on day 5. Mice were injected with 5 mg/kg cisplatin or PBS solution in the abdominal cavity once a week for 3 weeks. The tumor volume was measured and calculated. The formula volume = ½ (larger diameter)×(smaller diameter)×(smaller diameter). The animal experiments were approved by the Ethics Committee of The First Affiliated Hospital of Wannan Medical College.

2.13 | Hematoxylin–eosin and immunohistochemistry staining

Tumor tissues of the mice were fixed in 4% paraformaldehyde and then embedded in paraffin. After embedding and sectioning, the tumor tissues were stained with H&E. Immunohistochemistry staining was carried out using an anti-Ki-67 mAb (Cell Signaling Technology). The protein expression levels of Ki-67 in tumor tissues were observed under microscopy.

2.14 | Statistical analysis

The data are presented as the mean±SD. The statistical analyses were undertaken using a two-tailed Student's t-test or ANOVA, which was used to analyze the differences when there were more than two groups. The statistical analyses were carried out using SPSS 19.0 software. P values less than 0.05 were considered to be statistically significant.

3 | RESULTS

3.1 | Fat mass and obesity-associated protein is a potential target of cisplatin resistance in gastric cancer cells

CCK-8 assays were used to examine the effects of cisplatin on the viability of gastric cancer cells and cisplatin-resistant cells. Compared with SGC-7901 cells, cisplatin-resistant cells (SGC-7901/DDP) showed significant resistance to cisplatin treatment. The IC_{50} value of cisplatin in SGC-7901/DDP cells was significantly higher than that in SGC-7901 cells (SGC-7901/DDP, 16.29±3.58 μM vs. SGC-7901, 3.18±0.40 μM; Figure 1A,B). To clarify the relationship between m^6A methylation modification and cisplatin resistance of gastric cancer, we first quantified the m^6A methylation content in total RNAs and the protein expression of m^6A methyltransferases and demethylases in GES-1, SGC-7901, and SGC-7901/DDP cells. As shown in Figure 1C, the m^6A levels in total RNAs were obviously decreased in SGC-7901/DDP cells compared to that in GES-1 and SGC-7901 cells. Furthermore, FTO expression was dramatically upregulated in SGC-7901/DDP cells, while the expression levels of METTL3, METTL14, FTO, and ALKBH5 were considerably less pronounced (Figure 1D,E). To further investigate the effects of FTO on cisplatin resistance, we knocked down FTO by shRNAs (shFTO-1 and shFTO-2) and overexpressed FTO by pcDNA3.1 plasmid in SGC-7901/DDP and SGC-7901 cells (Figure 1F–H). Knockdown or overexpression of FTO did not affect the cell viability of SGC-7901 or SGC-7901/DDP cells (Figure 1J). However, FTO silencing obviously enhanced the sensitivity of SGC-7901/DDP cells to cisplatin (Figure 1K). We also observed that FTO overexpression significantly reduced the sensitivity of SGC-7901 cells to cisplatin (Figure 1L). These results indicate that m^6A demethylase enzyme FTO mediates cisplatin resistance of gastric cancer cells.

3.2 | Fat mass and obesity-associated protein promotes cisplatin resistance by facilitating autophagy in gastric cancer cells

Autophagy is a common cellular process in eukaryotic cells, which is largely involved in the cisplatin resistance of tumors.\(^6,27,28\) During autophagy, LC3 I is converted to LC3 II through lipida-
Consequently, degradation of P62 and accumulation of LC3 II (bottom LC3 band) are indicators of autophagy induction. To explore whether FTO mediated autophagy in cisplatin-resistant and cisplatin-sensitive gastric cancer cells, protein levels of the autophagy markers LC3B and P62 were measured to determine the autophagy activation. The results showed that the expression of LC3B II was significantly decreased while the P62 expression was obviously increased in SGC-7901/DDP cells with FTO silencing (Figure 2A,B). However, overexpression of FTO by plasmid dramatically increased LC3B II expression and reduced P62 level in SGC-7901 cells (Figure 2C,D). In addition, immunofluorescence assays showed that knockdown of FTO significantly reduced the formation of LC3B puncta in SGC-7901/DDP cells, whereas LC3B puncta was enhanced in FTO-overexpressed SGC-7901 cells (Figure 2E). The results of TEM images also revealed that FTO silencing reduced the number of autophagosomes in SGC-7901/DDP cells. In contrast, overexpression of FTO increased the number of autophagosomes in SGC-7901 cells (Figure 2F).

To further confirm the roles of autophagy in cisplatin resistance, we used 3-methyladenine and chloroquine to inhibit autophagy and found that inhibiting autophagy reversed the cisplatin resistance of SGC-7901/DDP cells (Figure 2G-I).
To identify potential target genes of FTO in autophagy, we undertook qRT-PCR assays to determine the mRNA expression changes of autophagy-related genes following FTO knockdown in SGC-7901/DDP cells. Similar to the results obtained from cervical cancer HeLa cells, the level of ULK1 mRNA was significantly downregulated after FTO knockdown, while mRNA levels of ATG5, ATG7, and BECLIN1 were not evidently changed (Figure 3A). As shown in Figure 3B–D, under- and overexpression of FTO markedly decreased and increased protein levels of ULK1, respectively, in SGC-7901/DDP cells. To further confirm the effects of ULK1 on autophagy, we transfected SGC-7901/DDP cells with ULK1 siRNA, and discovered that knockdown of ULK1 significantly increased

3.3 Loss of FTO attenuates expression of ULK1

autophagy-related genes following FTO knockdown in SGC-7901/DDP cells. Similar to the results obtained from cervical cancer HeLa cells, the level of ULK1 mRNA was significantly downregulated after FTO knockdown, while mRNA levels of ATG5, ATG7, and BECLIN1 were not evidently changed (Figure 3A). As shown in Figure 3B–D, under- and overexpression of FTO markedly decreased and increased protein levels of ULK1, respectively, in SGC-7901/DDP and SGC-7901 cells transfected with FTO shRNA and FTO overexpression plasmids. (F) Transmission electron microscopy analysis of autophagosomes in SGC-7901/DDP and SGC-7901 cells transfected with FTO shRNA and FTO overexpression plasmids. Arrows indicate autophagosomes. (G, H) Western blot analysis of FTO, P62, and LC3B expression in SGC-7901/DDP cells after treatment with 5 μM 3-methyladenine (3-MA) or 10 μM chloroquine (CQ) for 24 h. (I) SGC-7901/DDP cells were pretreated with 3-MA or CQ for 1 h, and the cell viability was measured by CCK-8 assay after DDP treatment for 24 h. Results are presented as mean ± SD of n = 3–4 independent experiments. *p < 0.05 vs. negative control shRNA (shNC), negative control (NC), or control (Con) group. FTO, pcDNA3.1-FTO plasmid; shFTO, FTO shRNA
P62 expression and decreased LCB3 II protein level. In addition, the protein expression of phosphorylation of ATG13 S318 (P-ATG13) was downregulated, indicating that ULK1 activity decreased\(^\text{31,32}\) (Figure 3E,F). Moreover, knockdown of ULK1 obviously promoted the inhibitory effects of cisplatin on growth in SGC-7901/DDP cells (Figure 3G). These results indicate that ULK1 is functionally important for autophagy and cisplatin resistance in gastric cancer cells.

### 3.4 | Fat mass and obesity-associated protein regulates autophagy and cisplatin resistance through targeting ULK1 in an m\(^6\)A-dependent manner

To confirm whether FTO influenced autophagy and cisplatin resistance through targeting ULK1, we undertook rescue experiments and observed that ULK1 inhibition reversed the upregulated LC3B II, P-ATG13 and increased the downregulated P62 in SGC-7901/DDP cells with FTO overexpression (Figure 4A,B). In addition, immunofluorescence assays showed that the elevated LC3B puncta induced by FTO overexpression was compromised in SGC-7901/DDP cells when treated with siULK1 (Figure 4C). Overexpression of FTO significantly attenuated the inhibitory effects of cisplatin on growth in SGC-7901/DDP cells. Transfection with siULK1 obviously reversed these effects (Figure 4D). To further explore the potential underlying mechanisms of m\(^6\)A in autophagy regulation, MeRIP-qPCR and RIP-qPCR assays were carried out. As shown in Figure 4E, silencing of FTO significantly increased the m\(^6\)A levels on mRNA of ULK1 at three sites. Furthermore, RIP-qPCR analysis revealed that ULK1 was a direct target of FTO (Figure 4F). These results indicate that FTO regulates the expression of ULK1 in an m\(^6\)A-dependent manner.

### 3.5 | Fat mass and obesity-associated protein modulates ULK1 expression through YTHDF2

It is well known that m\(^6\)A methylation mediates targeted mRNAs by specific RNA-binding proteins. YTHDF2, a major m\(^6\)A reader, is reported to selectively bind and destabilize m\(^6\)A-modified mRNAs\(^\text{23,33}\). To investigate whether the expression of ULK1 was affected by YTHDF2, we treated SGC-7901/DDP cells with YTHDF2 siRNA and

---

\(^1\text{FTO, pcDNA3.1-FTO plasmid; shFTO, FTO shRNA; siULK1, ULK1 siRNA}\)
found that YTHDF2 silencing significantly increased the protein level of ULK1 and P-ATG13 (Figure 5A,B). The RIP-qPCR assays indicated the direct binding within YTHDF2 and ULK1 mRNA (Figure 5C). In addition, mRNA stability analysis showed that the decay of ULK1 mRNA was inhibited in SGC-7901/DDP cells transfected with or without ULK1 siRNA, and the cell viability was measured by CCK-8 assays after DDP treatment for 24h. (E) m^6^A levels of ULK1 mRNA were detected by methylated RNA immunoprecipitation (MeRIP)-quantitative PCR (qPCR) assays in SGC-7901/DDP cells transfected with shFTO. (F) RIP-qPCR assay was carried out using FTO Ab, and the enrichment of ULK1 was measured in SGC-7901/DDP cells transfected with FTO plasmid. Results are presented as mean ± SD of n = 3–4 independent experiments. *p < 0.05 vs. negative control (NC) or negative control shRNA (shNC) group; #p < 0.05 vs. pcDNA3.1-FTO plasmid (FTO) group.

shFTO, FTO shRNA; siULK1, ULK1 siRNA

FiguRe 4 Fat mass and obesity-associated protein (FTO) regulates autophagy and cisplatin (DDP) resistance through targeting Unc-51-like kinase 1 (ULK1) in an N^6^-methyladenosine (m^6^A)-dependent manner. (A, B) Western blot analysis of FTO, ULK1, P-ATG13, P62, and LC3B protein expression in FTO-overexpressed SGC-7901/DDP cells which were transfected with or without ULK1 siRNA. (C) Immunofluorescence images of LC3B puncta in SGC-7901/DDP cells treated in the same method as described above. (D) FTO-overexpressed SGC-7901/DDP cells were transfected with or without ULK1 siRNA, and the cell viability was measured by CCK-8 assays after DDP treatment for 24h. (E) m^6^A levels of ULK1 mRNA were detected by methylated RNA immunoprecipitation (MeRIP)-quantitative PCR (qPCR) assays in SGC-7901/DDP cells transfected with shFTO. (F) RIP-qPCR assay was carried out using FTO Ab, and the enrichment of ULK1 was measured in SGC-7901/DDP cells transfected with FTO plasmid. Results are presented as mean ± SD of n = 3–4 independent experiments. *p < 0.05 vs. negative control (NC) or negative control shRNA (shNC) group; #p < 0.05 vs. pcDNA3.1-FTO plasmid (FTO) group.

shFTO, FTO shRNA; siULK1, ULK1 siRNA

3.6 | Knockdown of FTO improves the sensitivity of cisplatin-resistant gastric cancer cells to cisplatin in vivo

We finally explored the effects of FTO knockdown on tumor formation using nude mice xenograft experiments. Either control or FTO-silenced SGC-7901/DDP cells were injected subcutaneously in the flanks of male nude mice. Mice were injected with cisplatin or PBS solution in the abdominal cavity. In nude mice xenografts, the volume of tumors that carried FTO shRNA showed significantly slower growth than in the shNC group when the mice treated with DDP (Figure 6A,B). Although the data from H&E staining had no obvious difference between groups, knockdown of FTO inhibited cell proliferation in DDP-treated nude mice as evidenced by the decreased Ki-67 staining on the xenograft (Figure 6C,D). Consistent with the data of the in vitro study, FTO knockdown alleviated protein expression of ULK1 and LC3B II while elevating P62 protein abundance (Figure 6E,F). Taken together, these results suggest that FTO silencing could increase the sensitivity of cisplatin through inactivating ULK1-dependent autophagy in vivo.

4 | DISCUSSION

The m^6^A modification is one of the most crucial RNA modifications in human malignant diseases. N^6^-methyladenosine modification plays a crucial role in regulating gene expression through RNA splicing, stability, translocation, and translation. The expression
levels of m^6A regulators, including writers, erasers, and readers, are usually dysregulated in cancers, which contributes to drug resistance and cancer relapse. 38–40 Expression of METTL3 is downregulated in sorafenib-resistant hepatocellular carcinoma and triggered degradation of FOXO3, which elevates autophagy-induced sorafenib resistance. 41 The FTO-mediated m^6A demethylation regulates mRNA stability of MERTK, then controls TKI resistance. 42 However, few studies have focused on the roles of m^6A modification in regulating drug resistance for gastric cancer.

In the present study, we first revealed the relationship between m^6A RNA modification and cisplatin resistance. The m^6A levels in total RNAs were obviously decreased in SGC7901/DDP cells, which was attributed to the upregulation of FTO. Furthermore, knockdown of FTO in cisplatin-resistant SGC7901/DDP cells increased the reactivity to cisplatin, whereas overexpression of FTO in cisplatin-sensitive SGC7901 cells decreased the cisplatin sensitivity. These results indicate the direct roles of FTO-mediated m^6A modification in cisplatin resistance of gastric cancer.

Previous studies have indicated that FTO positively regulates autophagy in cervical cancer HeLa cells 24 and mouse pre-adipocyte 3T3-L1 cells. 23 Autophagy functions as a protective factor in resistance of cancer cells exposed to anticancer drugs. 28,43 Our data determined a similar modulatory role of FTO in mediating autophagy, and FTO-dependent cisplatin resistance in gastric cancer was regulated by promoting autophagy. Silencing FTO reduced the number of autophagosomes and accumulation of LC3B II in gastric cancer cells, which indicated that suppression of autophagy might reverse the m^6A-dependent resistance to cisplatin.

To elucidate the mechanisms by which FTO mediated autophagy, we identified the target genes of autophagy following FTO knockdown. ATG5 and ATG7 are significantly attenuated following FTO knockdown in 3T3-L1 cells. 36 Knockdown of FTO positively regulates the expression of ULK1 in HeLa cells. 17 These results suggested that target genes involved in the FTO-mediated autophagy might be species- and cell-specific. We identified ULK1, but not ATG5 or ATG7, as a primary regulator connecting m^6A modification with autophagy.
in gastric cancer cells. ULK1 is essential for the recruitment of other autophagy-related proteins to initiate the autophagosome formation, linking cellular nutrient status to downstream events in autophagy. ULK1 forms a complex with ATG101, ATG13, and FIP200. Following autophagy induction, ULK1 can phosphorylate serine-318 (P-S318) in ATG13, which serves as an indicator for ULK1 activity. The expression of ULK1 protects tumor cells from excessive autophagy. Knockdown of ULK1 makes cells more sensitive to cisplatin in NSCLC cells. MicroRNA-489 directly targets ULK1 and negatively regulates its expression, and thus overcomes resistance to doxorubicin, tamoxifen, and cisplatin by inhibiting autophagy in breast cancer cells. Consistently, our results suggested that knockdown of ULK1 significantly inhibited autophagy and promoted the inhibitory effects on growth in SGC-7901/DDP cells treated with cisplatin, which indicated that ULK1 is functionally important for autophagy and cisplatin resistance in gastric cancer cells.

We further validated ULK1 as a direct target of FTO in an m6A-dependent manner in gastric cancer cells. Knockdown of FTO markedly reduced ULK1 expression at both mRNA and protein levels. Furthermore, by using MeRIP-qPCR assays with gene-specific primers according to the published data of the m6A-sequence, we found that FTO overexpression elevated m6A levels of ULK1 mRNA. The RIP-qPCR assay revealed a strong signal for ULK1 mRNA following overexpression of FTO, suggesting that ULK1 was the target of FTO. Previous study showed that m6A-modified mRNA tended to be less stable, which was largely attributed to the YTHDF2-mediated mRNA degradation. We treated SGC-7901/DDP cells with YTHDF2 siRNA and found that YTHDF2 silencing markedly increased ULK1 expression. The RIP-qPCR assay validated ULK1 as a direct target of YTHDF2. In addition, mRNA stability analysis indicated that the decay of ULK1 mRNA was inhibited when transfected with YTHDF2 siRNA. To confirm whether FTO regulated ULK1-mediated autophagy through YTHDF2, we undertook rescue experiments and observed that knockdown of YTHDF2 could reverse the downregulation of ULK1 and the inhibitory effects of cisplatin on growth in SGC-7901/DDP cells with FTO silencing.

In summary, the present study reveals a critical role of FTO in mediating cisplatin resistance of gastric cancer cells. Upregulated FTO promotes autophagy-induced cisplatin resistance by regulating
YTHDF2-related ULK1 expression in cisplatin-resistant gastric cancer cells. Our findings clarify the underlying mechanisms through which m^6^A mRNA methylation functions in cisplatin-resistant gastric cancer cells, suggesting a potential therapeutic target.

**AUTHOR CONTRIBUTIONS**

W.-P.D. and F.-Y.D. designed the experiment and supervised the project. Y.Z., L.-X.G., W.W., and T.Z. performed the experiments. F.-Y.D. and W.-P.D. analyzed the data and drafted the manuscript. Y.Z. and W.-P.D. were responsible for critical reading, editing, and revising the manuscript. All authors read and approved the final manuscript.

**ACKNOWLEDGMENTS**

This study was supported by the grants from the Key University Science Research Project of Anhui Province (KJ2020AQ054 and KJ2021A0827) and the Key Project Research Fund of Wannan Medical College (WK2020ZF19).

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study are available on request to the corresponding author.

**ETHICS STATEMENT**

Approval of the research protocol by an institutional review board: N/A.

Informed consent: N/A.

Registry and registration no. of the study/trial: N/A.

Animal studies: The animal experiments were approved by the Ethics Committee of The First Affiliated Hospital of Wannan Medical College.

**ORCID**

Wen-ping Ding https://orcid.org/0000-0002-4252-8212

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
2. Iwatsuki M, Yamamoto H, Miyata H, et al. Effect of hospital and surgeon volume on postoperative outcomes after distal gastrectomy for gastric cancer based on data from 145,523 Japanese patients collected from a nationwide web-based data entry system. Gastric Cancer. 2019;22(1):190-201.
3. Yuan L, Xu ZY, Ruan SM, Mo S, Qin JJ, Cheng XD. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Mol Cancer. 2020;19(1):96.
4. Biagnoni A, Skalamera I, Peri S, et al. Update on gastric cancer treatments and gene therapies. Cancer Metastasis Rev. 2019;38(3):537-548.
5. Yimit A, Adebali O, Sancar A, Jiang Y. Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs. Nat Commun. 2019;10:309.

6. Kim M, Jung JY, Choi S, et al. GFRα1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy. Autophagy. 2017;13(1):149-168.
7. Guo J, Satoh K, Tabata S, Mori M, Tomita M, Soga T. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells. BMC Cancer. 2021;21:174.
8. Bahar E, Kim JY, Yoon H. Chemotherapy resistance explained through endoplasmic reticulum stress-dependent signaling. Cancers (Basel). 2019;11(3):338.
9. Lin TY, Chan HH, Chen SH, et al. BIRC5/Survivin is a novel ATG12-ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells. Autophagy. 2020;16(7):1296-1313.
10. Zhang X, Zeng X, Liang X, et al. The chemotherapeutic potential of PEG-b-PLGA copolymer micelles that combine chloroquine as autophagy inhibitor and doxetaxel as an anti-cancer drug. Biomaterials. 2014;35(33):9144-9154.
11. Yang C, Pan Y. Fluorouracil induces autophagy-related gastric carcinoma cell death through BcL-1 upregulation by miR-30 suppression. Tumour Biol. 2015;37:15489-15494.
12. Zeng X, Zhao H, Li Y, et al. Targeting hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Autophagy. 2015;11:355-372.
13. Kumar A, Singh UK, Chaudhary A. Targeting autophagy to overcome drug resistance in cancer therapy. Future Med Chem. 2015;7(12):1535-1542.
14. Li LQ, Xie WJ, Pan D, Chen H, Zhang L. Inhibition of autophagy by bafilomycin A1 promotes chemosensitivity of gastric cancer cells. Tumour Biol. 2016;37(1):653-659.
15. Xi G, Hu X, Wu B, et al. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett. 2011;307:141-148.
16. Yu YF, Hu PC, Wang Y, et al. Paclitaxel induces autophagy in gastric cancer BGC823 cells. Ultrastruct Pathol. 2014;37:284-290.
17. Tamargo-Gómez I, Mariño G. AMPK: Regulation of metabolic dynamics in the context of autophagy. Int J Mol Sci 2018. 19(12):3812.
18. Tang F, Hu P, Yang Z, et al. SB1005965, a novel inhibitor of Ulk1, suppresses nonsmall cell lung cancer cell growth by modulating both autophagy and apoptosis pathways. Oncol Rep. 2017;37(6):3449-3458.
19. Zhao Z, Li J, Jiang Y, Xu W, Li X, Jing W. CLDN1 increases drug resistance of non-small cell lung cancer by activating autophagy via up-regulation of ULK1 phosphorylation. Med Sci Monit. 2017;23:2906-2916.
20. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608-624.
21. Wang Y, Li Y, Toth JI, Peterski MD, Zhang Z, Zhao JC. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat Cell Biol. 2014;16(2):191-198.
22. Berulava T, Buchholz E, Elerdashvili V, et al. Changes in m^6^A RNA methylation contribute to heart failure progression by modulating translation. Eur J Heart Fail. 2020;22(1):54-66.
23. Wang X, Wu R, Liu Y, et al. m^6^A mRNA methylation controls heart failure progression by modulating translation. Eur J Heart Fail. 2020;22(1):54-66.
24. Jin S, Zhang X, Miao Y, et al. m^6^A RNA modification controls autophagy through upregulating ULK1 protein abundance. Cell Res. 2018;28(9):955-957.
25. Zhou S, Bai ZL, Xia D, et al. FTO regulates the chemoradiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. Mol Carcinog. 2018;57(5):590-597.
26. Ma M, Zhang Y, Weng M, et al. IncRNA GCAWKR promotes gastric cancer development by scaffolding the chromatin modification factors WDR5 and KAT2A. Mol Ther. 2018;26(11):2658-2668.
27. Guo WJ, Zhang YM, Zhang L, et al. Novel monofunctional platinum (II) complex mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin. *Autophagy*. 2013;9(7):996-1008.

28. Peng L, Sang H, Wei S, et al. circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2. *Mol Cancer*. 2020;19(1):156.

29. Ichimura Y, Kirisako T, Takao T, et al. A ubiquitin-like system mediates protein lipidation. *Nature*. 2000;408:488-492.

30. Komatsu M, Waguri S, Koike M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. *Cell*. 2007;131:1149-1163.

31. Shoemaker CJ, Huang TQ, Weir NR, Polyakov NJ, Schultz SW, Denic V. CRISPR screening using an expanded toolkit of autophagy reporters identifies TMEM41B as a novel autophagy factor. *PLoS Biol*. 2019;17:e2007044.

32. Wang C, Wang H, Zhang D, et al. Phosphorylation of ULK1 affects autophagosome fusion and links chaperone-mediated autophagy to macroautophagy. *Nat Commun*. 2018;9:3492.

33. Liu Y, You Y, Lu Z, et al. N6-methyladenosine RNA modification-mediated cellular metabolism rewiring inhibits viral replication. *Science*. 2019;365(6458):1171-1176.

34. Choe J, Lin S, Zhang W, et al. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. *Nature*. 2018;561(7724):556-560.

35. Weng H, Huang H, Wu H, et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. *Cell Stem Cell*. 2018;22(2):191-205.e9.

36. Min KW, Zealy RW, Davila S, et al. Profiling of m6A RNA modifications identified an age-associated regulation of AGO2 mRNA stability. *Aging Cell*. 2018;17(3):e12753.

37. Ma S, Chen C, Ji X, et al. The interplay between m6A RNA methylation and noncoding RNA in cancer. *J Hematol Oncol*. 2019;12(1):121.

38. Feng ZY, Gao HY, Feng TD. Immune infiltrates of m6A RNA methylation-related IncRNAs and identification of PD-L1 in patients with primary head and neck squamous cell carcinoma. *Front Cell Dev Biol*. 2021;9:672248.

39. Zheng W, Dong X, Zhao Y, et al. Multiple functions and mechanisms underlying the role of METTL3 in human cancers. *Front Oncol*. 2019;9:1403.

40. Lan Q, Liu PY, Haase J, Bell JL, Hüttelmaier S, Liu T. The critical role of RNA m6A methylation in cancer. *Cancer Res*. 2019;79(7):1285-1292.

41. Lin Z, Niu Y, Wan A, et al. RNA m6a methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. *EMBO J*. 2020;39(2):e103181.

42. Yan F, Al-Kali A, Zhang Z, et al. A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. *Cell Res*. 2018;28(11):1062-1076.

43. Wang J, Zhou JY, Kho D, Reiners JJ Jr, Wu GS. Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy. *Autophagy*. 2016;12(10):1791-1803.

44. Lin MG, Hurley JH. Structure and function of the ULK1 complex in autophagy. *Curr Opin Cell Biol*. 2016;39:61-68.

45. Hosokawa N, Sasaki T, Iemura S, Natsume T, Hara T, Mizushima N. Atg101, a novel mammalian autophagy protein interacting with Atg13. *Autophagy*. 2009;5:973-979.

46. Lechauve C, Keith J, Khandros E, et al. The autophagy-activating kinase ULK1 mediates clearance of free α-globin in β-thalassemia. *Sci Transl Med*. 2019;11(506):eaav4881.

47. Quan Y, Lei H, Wahafu W, Liu Y, Ping H, Zhang X. Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer. *Biomed Pharmacother*. 2019;120:104990.

48. Liu L, Yan L, Liao N, Wu WQ, Shi JL. A review of ULK1-mediated autophagy in drug resistance of cancer. *Cancers (Basel)*. 2020;12(2):352.

49. Soni M, Patel Y, Markoutsa E, et al. Autophagy, cell viability, and chemoresistance are regulated by miR-489 in breast cancer. *Mol Cancer Res*. 2018;16(9):1348-1360.

50. Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. *Nature*. 2014;505(7481):117-120.

---

**How to cite this article:** Zhang Y, Gao L-x, Wang W, Zhang T, Dong F-y, Ding W-p. M6A demethylase fat mass and obesity-associated protein regulates cisplatin resistance of gastric cancer by modulating autophagy activation through ULK1. *Cancer Sci*. 2022;113:3085-3096. doi: 10.1111/cas.15469